{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"groups":[{"description":"Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.\n\nlenalidomide: Given PO","id":"OG000","title":"Treatment (Lenalidomide)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who received lenalidomide on study","reportingStatus":"POSTED","timeFrame":"Up to 9 years","title":"Number of Patients Who Experience Improvement in GVHD on Lenalidomide, Defined as the Reduction in Severity of GVHD as Defined by the National Institutes of Health (NIH) Consensus Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}